Acute Migraine Drugs Market

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient?s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate?severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
Acute Migraine Drugs Market contains market size and forecasts of Acute Migraine Drugs in global, including the following market information:
Global Acute Migraine Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Acute Migraine Drugs Market Sales, 2017-2022, 2023-2028, (K Unit)
Global top five Acute Migraine Drugs companies in 2021 (%)
The global Acute Migraine Drugs market was valued at 2165.3 million in 2021 and is projected to reach US$ 3473.9 million by 2028, at a CAGR of 7.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Triptans Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acute Migraine Drugs include GSK, Teva, Pfizer, Novartis, Sun Pharma, Grunenthal, Endo Pharmaceuticals, Merck and J & J. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Acute Migraine Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Migraine Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Acute Migraine Drugs Market Segment Percentages, by Type, 2021 (%)
Triptans
NSAIDs
Others
Global Acute Migraine Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Acute Migraine Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Drug Stores
Global Acute Migraine Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Acute Migraine Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Migraine Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Acute Migraine Drugs revenues share in global market, 2021 (%)
Key companies Acute Migraine Drugs sales in global market, 2017-2022 (Estimated), (K Unit)
Key companies Acute Migraine Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J